Biotech IPOs Surge Into August as SpaceX Lockup Tests the Float

The IPO market has spent much of 2026 waiting for a signal that the window is widening beyond AI infrastructure names. The first full week of August delivered one — not from tech, but from biotech. Four pharmaceutical companies priced upsized offerings totaling $1.17 billion, every one of them increasing deal size at pricing. Meanwhile, the largest lockup expiry in recent memory freed up to 912 million SpaceX shares, and the SEC advanced a proposal to rescind the foundational trade-through rule that has governed U.S. equity execution for two decades. Each of these threads points in a different direction, but together they sketch the outlines of a market where issuance is recovering, float is expanding rapidly, and the plumbing underneath all of it may be about to change.

The Biotech Wave: Upsized, Above Range, Well-Received

The week of August 3 saw six IPOs and five SPACs price, with two additional IPOs and eight SPACs filing initial paperwork^[1]. The dominant story was the biotech cohort, which collectively raised more than $1.17 billion across four deals — all of them upsized at pricing, an unusual signal of demand outstripping supply^[2].

Source: Renaissance Capital weekly recap, August 7, 2026}

Braveheart Bio (BRVE) was the standout. The cardiovascular biotech priced 21.25 million shares at $18.00 — a full dollar above the top of its range — to raise $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is an oral cardiac myosin inhibitor licensed from China’s Hengrui Pharmaceuticals, targeting both obstructive and non-obstructive hypertrophic cardiomyopathy. A global Phase 3 trial is planned for the second half of 2026^[1]. The stock finished its first week up 67%, suggesting the market is willing to pay up for late-stage clinical assets with clear regulatory paths.

Latigo Biotherapeutics (LTGO) raised $346 million at the top of its range, pricing 19.2 million shares at $18.00. Its lead drug, LTG-001, is an oral Nav1.8 inhibitor for acute pain — a non-opioid mechanism that has drawn significant pharmaceutical interest. Phase 3 trials are planned for 2H26, with topline results expected in 2H27^[1].

Attovia Therapeutics (ATTO) priced at the high end to raise $289 million at a $767 million market cap. The company is developing biologic therapies for immune-mediated diseases using its ATTOBODY nanobody platform, with a lead candidate targeting IL-31 for chronic pruritus in atopic dermatitis. Phase 1 dosing was completed in Q1 2026, and a Phase 2 trial is planned for 1H27^[1].

BlossomHill Therapeutics (BLSM) rounded out the cohort at $150 million, pricing at the midpoint of its range. Its EGFR-mutant non-small cell lung cancer program is in a global Phase 1/2 trial, with plans to seek an end-of-Phase 1 meeting with the FDA in Q4 2026^[1].

Reading the pattern

What makes this week notable is not any single deal but the uniformity of the upsizing. Every biotech increased share count or priced above range. That is a demand signal — bookrunners Goldman Sachs, Jefferies, J.P. Morgan, Leerink Partners, and Guggenheim all had sufficient order books to push deal sizes higher^[2]. The question is whether this extends beyond biotech, where clinical-stage companies with defined catalyst timelines tend to attract specialized investors who price risk differently from generalist funds.

The broader 2026 IPO scorecard tells a more mixed story. Through August 7, 110 IPOs have priced (excluding SPACs), with 62 trading above issue price, 44 below, and 4 unchanged — a total return of 6.85% from issue price^[2]. The Renaissance IPO Index is up 18.8% year-to-date, outpacing the S&P 500’s 13.4% gain^[1]. The index’s top holdings include Astera Labs (ALAB) and CoreWeave (CRWV), suggesting AI infrastructure remains the dominant force in IPO performance even as biotech takes the near-term calendar.

SpaceX: The Lockup That Could Reshape the Float

SpaceX’s staggered lockup schedule frees an additional 12.9 billion shares by mid-2027, reshaping the float in increments rather than all at once.

While biotechs were pricing upsized deals, SpaceX (SPCX) was navigating what one institutional broker called “the most talked-about lockup in the history of IPO lockups”^[3].

On August 6, the first tranche of SpaceX’s staggered lockup expired, making up to 912 million of the company’s roughly 13.6 billion outstanding shares eligible for sale^[3]. That single release could more than double the public float, and if a price-based early-release provision is triggered, it could more than triple it^[3]. The staggered schedule will free an additional 12.9 billion shares by mid-2027^[3].

CEO Elon Musk’s approximately 42% stake remains locked under a separate agreement until June 2027 — one year after the IPO^[3]. Executive officers are also subject to longer lockups that generally do not begin expiring until after fourth-quarter results. The immediate selling pressure comes from employees and early investors sitting on substantial gains.

The stock has already absorbed significant pressure. SpaceX shares fell roughly 8.5% on August 5 after reporting Q2 earnings — despite a 92% jump in revenue — as investors focused on capital spending and free cash flow. The company’s CFO said on the earnings call that SpaceX is on track for $100 billion in annualized revenue by year-end^[3]. Through the lockup expiry, the stock was down 49% from its June IPO high^[3].

The critical variable is not how many shares become eligible but who sells. Brokers report that some pre-IPO investors are eager to diversify into other private-market opportunities, including Anthropic, OpenAI, and Anduril Industries^[3]. If early backers like Founders Fund, Craft Ventures, or Alphabet trim positions meaningfully, that will be read as a confidence signal. If they hold, the float expansion becomes a liquidity event rather than a valuation event.

I would put the probability of significant near-term selling at roughly 65/35. The gains are large, the lockup was long anticipated, and the staggered structure actually encourages earlier selling — investors who wait risk that later tranches will flood the market at worse prices. The offsetting factor is that SpaceX’s believers are unusually conviction-driven; this is not a typical venture-backed cohort.

The SEC’s Reg NMS Proposal: Rewiring the Plumbing

The SEC’s proposal to rescind Rule 611 would shift the governing framework from rigid intermarket routing to broker-level best execution under FINRA Rule 5310.

On June 11, 2026, the SEC proposed rescinding Rule 611 (the trade-through prohibition) and Rule 610(e) (the locked and crossed markets prohibition) of Regulation NMS — the rules that have formed the backbone of U.S. equity market structure since 2005^[4]. If adopted, the rescission would eliminate the National Best Bid and Offer (NBBO) as a hardwired execution requirement and replace it with a best-execution framework governed by FINRA Rule 5310^[5].

The market the SEC is regulating looks nothing like the one Rule 611 was written for. In 2005, eight national securities exchanges traded NMS stocks. Today there are 17 operating exchanges, with three more approved^[5]. Rule 611 effectively guaranteed that any new exchange displaying protected quotes would receive order flow and connectivity revenue, incentivizing exchange proliferation and fragmenting liquidity^[5]. Off-exchange trading — alternative trading systems, dark pools, single-dealer platforms, and wholesalers — has regularly exceeded 50% of total volume since the end of 2024^[5].

The SEC’s argument is straightforward: trading is now electronic, routing is automated, and market data is widely available, making the rigid trade-through protection of 2005 less necessary. Rescinding the rule would give trading centers more flexibility to compete for order flow and would reduce the artificial incentive for exchange creation^[5].

The tokenized equity angle

The proposal also fits within Chairman Paul Atkins’ broader “Project Crypto” mandate, which aims to modernize markets and allow trading to move on-chain^[5]. Rule 611 is structurally incompatible with automated market makers (AMMs) used in DeFi protocols — AMMs cannot route intermarket sweep orders or halt execution because a better quote exists on another exchange^[5]. Removing the trade-through rule would clear a regulatory path for tokenized equity trading on-chain, where execution against liquidity pools operates on a fundamentally different model than traditional lit exchanges.

Whether this materializes in the near term is a separate question. The proposal is out for comment, and adoption is not guaranteed. But the direction of travel is clear: the SEC is signaling that the post-2005 market structure framework is open for revision, and that on-chain markets are part of the design space.

What to Watch Next

1. Londian Wason (FOIL) — The sole sizable IPO on next week’s calendar is a China-based copper foil producer for lithium-ion batteries, aiming to raise $75 million at a $1.6 billion market cap. Anchored investors have indicated on $87 million, or 115% of the offering at the midpoint — a positive demand signal but for a very different sector than biotech^[6]. This will test whether the window extends beyond pharmaceutical names.

2. SpaceX lockup absorption — The first tranche has expired. Watch volume and price action over the next two weeks for evidence of how much insider supply is actually hitting the market. The staggered structure means every subsequent earnings cycle will bring another release.

3. Six IPO lockup releases next week — Renaissance Capital identifies six lockup expirations in the coming week, which will add supply to recent new issues. Lockup releases are typically negative for share prices in the short term, but the magnitude depends on the specific stock’s trading liquidity and insider composition^[6].

4. Reg NMS comment period — The SEC’s proposal is in the public comment phase. Watch for submissions from major exchanges, broker-dealers, and institutional investors, which will signal how contentious adoption will be. Jones Day notes that if finalized, the rescission would affect routing obligations, connectivity costs, and the competitive landscape for every venue trading NMS stocks^[5].

5. Robinhood Ventures Fund II (RVII) — Not counted in IPO statistics, but Robinhood’s second private-tech closed-end fund plans to raise $200 million via Goldman Sachs, holding dozens of smaller tech startup positions. It will test retail appetite for pre-IPO exposure in a structured vehicle^[6].

This article is research commentary, not investment advice. All IPO data is sourced from Renaissance Capital and IPOScoop as of August 7, 2026. Lockup and SpaceX details are sourced from Reuters reporting as of August 5, 2026. SEC regulatory analysis is sourced from the SEC’s proposed rule release and legal commentary from Jones Day, WilmerHale, and Skadden.